## **Accepted Manuscript**

Development of novel avenues to overcome challenges facing CAR T cells

Soyeon Kim, Edmund K. Moon

PII: S1931-5244(17)30209-8

DOI: 10.1016/j.trsl.2017.05.009

Reference: TRSL 1157

To appear in: Translational Research

Received Date: 11 March 2017

Revised Date: 4 May 2017

Accepted Date: 30 May 2017

Please cite this article as: Kim S, Moon EK, Development of novel avenues to overcome challenges facing CAR T cells, *Translational Research* (2017), doi: 10.1016/j.trsl.2017.05.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



<u>Development of novel avenues to overcome challenges facing CAR T cells</u>

Soveon Kim<sup>1</sup>, Edmund K. Moon<sup>1</sup>

1. Division of Pulmonary, Allergy, and Critical Care; Perelman School of Medicine at the

University of Pennsylvania; Philadelphia, PA

Corresponding author: Edmund K. Moon (edmund.moon@uphs.upenn.edu)

Office phone number: (215) 908-1454

University of Pennsylvania/Pulmonary

Stemmler Hall, 2nd Floor, Lab 261

3450 Hamilton Walk

Philadelphia, PA 19104

Abbreviated Title: Augmenting CAR T cells

**Abstract** 

There has been dramatic success in treating patients with adoptive transfer of

autologous T cells genetically modified to express a chimeric antigen receptor (CAR)

redirecting them to the antigen CD19. Despite this success, the application of CAR T

cell therapy in solid malignancies has encountered many challenges that need to be

overcome if similar success across other cancers is to become a reality. These

challenges can be classified into six categories: the heterogeneity of tumor cell clones

and tumor-associated antigen expression; poor T cell trafficking into the tumor site; poor

T cell survival and persistence; the presence of suppressive immune cells; the secretion

of suppressive soluble factors in the tumor microenvironment; the upregulation of T cell

## Download English Version:

## https://daneshyari.com/en/article/5684959

Download Persian Version:

https://daneshyari.com/article/5684959

<u>Daneshyari.com</u>